Download PDF
1 / Pages

Other users also viewed these articles

Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn¿s Disease and Ulcerative Colitis Francisco Rodríguez-Moranta; Federico Argüelles-Arias; Joaquín Hinojosa del Val; Marisa Iborra Colomino; M. Dolores Martín-Arranz; Luis Menchén Viso; Fernando Muñoz Núñez; Elena Ricart Gómez; José Germán Sánchez-Hernández; Teresa Valdés-Delgado; Jordi Guardiola Capón; Manuel Barreiro-de Acosta; Míriam Mañosa Ciria; Yamile Zabana Abdo; Ana Gutiérrez Casbas;
Gastroenterol Hepatol. 2024;47:522-52
Real-world experience of vedolizumab use in Colombian patients with inflammatory bowel disease¿EXVEDOCOL Viviana Parra; Sandra Cifuentes; Sandra Avendaño; Enrique Ponce de León; Cristian Florez; Gustavo Reyes; Fabian Puentes; Manuel Ballesteros; Edilberto Nuñez; Federico Gómez; Juan Ricardo Márquez;
Gastroenterol Hepatol. 2024;47:858-66
Perception and clinical decisions from inflammatory bowel diseases¿ specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB) Roberta Krause Romero; Daniela Oliveira Magro; Natalia Sousa Freitas Queiroz; Aderson Omar Mourão Cintra Damião; Fabio Vieira Teixeira; Rodrigo Bremer Nones; Ligia Yukie Sassaki; Rogerio Saad-Hossne; Paulo Gustavo Kotze;
Gastroenterol Hepatol. 2022;45:499-506